In short
Recent clinical trials are investigating the use of Fluoroethoxybenzovesamicol F-18 to better understand the role of cholinergic and dopaminergic systems in apathy following stroke. This innovative research aims to shed light on the pathophysiology of apathy and potentially pave the way for improved treatments for stroke patients.
At a glance
- Study Drug
- Fluoroethoxybenzovesamicol F-18
- Primary Objective
- Compare cholinergic and dopaminergic pathways in apathetic and non-apathetic stroke patients
- Participant Age Range
- 18-75 years
- Time Since Stroke
- 3-7 months
- Imaging Techniques
- PET scan, MRI
- Main Outcomes Measured
- Binding intensities of tracers, clinical severity of apathy, brain connectivity, white matter structure, cerebral blood flow
- Potential Impact
- Better understanding of apathy mechanisms in stroke patients, possible development of targeted treatments
What is FLUOROETHOXYBENZOVESAMICOL F-18 (FEOBV F-18)?
FLUOROETHOXYBENZOVESAMICOL F-18, also known as FEOBV F-18 or (18F)Fluoroethoxybenzovesamicol, is a diagnostic tool used in medical imaging. It is a radioactive tracer that helps doctors see specific areas of the brain during a special type of scan called a PET scan (Positron Emission Tomography). This substance is not a medication that treats a condition, but rather a tool to help understand what's happening in the brain.
Purpose of the Study
Researchers are using FEOBV F-18 to study apathy in stroke patients. Apathy is a condition where a person loses interest or motivation in daily activities. The main goal of this study is to compare the brain activity in stroke patients with and without apathy, focusing on two important brain systems:
- Cholinergic system: This system uses a chemical called acetylcholine and is important for attention, memory, and motivation.
- Dopaminergic system: This system uses dopamine and is involved in reward, motivation, and pleasure.
By comparing these systems between apathetic and non-apathetic stroke patients, researchers hope to better understand why some people develop apathy after a stroke.
How is FEOBV F-18 Used?
FEOBV F-18 is given as an injection solution. During the study, participants will receive this injection before undergoing a PET scan. The maximum dose used in this study is 262.5 MBq (megabecquerels), which is a measure of radioactivity. This allows researchers to see how the cholinergic system is functioning in different parts of the brain.
Who Can Participate in the Study?
The study is looking for specific types of participants:
- Adults aged 18 to 75 years old
- People who have had a stroke 3 to 7 months ago
- Individuals with a Rankin score (a measure of disability) of 2 or less
- Participants may or may not have apathy (determined by a special scale)
- Those who are able to provide informed consent
Who Cannot Participate in the Study?
Some people cannot participate in this study for safety reasons. These include:
- People over 75 years old
- Those who cannot have an MRI or PET scan (e.g., due to metal implants or claustrophobia)
- Individuals with known allergies to the study materials
- People taking certain medications that affect the cholinergic or dopaminergic systems
- Those with severe heart failure or certain brain abnormalities
- Pregnant or breastfeeding women
- People with chronic neurological disorders or severe psychiatric conditions
What Will Be Measured?
The study will look at several factors:
- The intensity of FEOBV F-18 binding in the brain, which shows cholinergic activity
- The severity of apathy symptoms
- Brain connectivity patterns using MRI
- Changes in brain structure using special MRI techniques
- Blood flow in the brain
Safety Considerations
While FEOBV F-18 is used for diagnosis and not treatment, there are still some safety considerations:
- The injection contains a small amount of radioactive material, which is carefully controlled
- Participants will be screened for any conditions or medications that might interact with the study procedures
- The study excludes pregnant or breastfeeding women due to potential risks from radiation exposure
- Multiple follow-up visits are required to ensure participant safety and gather necessary data
This study aims to improve our understanding of apathy after stroke, which could lead to better treatments in the future. If you or someone you know has had a stroke and might be interested in participating, it's important to discuss this with a healthcare provider to understand all the potential risks and benefits.